1,2,3,4-Tetrahydro-1,5-naphthyridine - CAS 13993-61-8
Catalog: |
BB057668 |
Product Name: |
1,2,3,4-Tetrahydro-1,5-naphthyridine |
CAS: |
13993-61-8 |
Synonyms: |
1,2,3,4-tetrahydro-1,5-naphthyridine; 1,2,3,4-tetrahydro-[1,5]naphthyridine; 1,5-NAPHTHYRIDINE, 1,2,3,4-TETRAHYDRO- |
IUPAC Name: | 1,2,3,4-tetrahydro-1,5-naphthyridine |
Description: | 1,2,3,4-Tetrahydro-1,5-naphthyridine can be used as SHP2 inhibitors to treat diseases. |
Molecular Weight: | 134.17 |
Molecular Formula: | C8H10N2 |
Canonical SMILES: | C1CC2=C(C=CC=N2)NC1 |
InChI: | InChI=1S/C8H10N2/c1-3-7-8(9-5-1)4-2-6-10-7/h1,3,5,10H,2,4,6H2 |
InChI Key: | OALXTMWCXNPUKJ-UHFFFAOYSA-N |
References: | Ciammaichella, A., et.al. PCT Int. Appl. WO 2021028362 A1, 212, (2021). |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
CN-113861128-A | Polymerizable compound and optically anisotropic body | 20211028 |
CN-113264876-A | Method for selectively catalyzing and hydrogenating aromatic heterocyclic compounds by non-hydrogen participation | 20210528 |
WO-2021233861-A1 | Azabicyclic(thio)amides as fungicidal compounds | 20200519 |
EP-3870261-A1 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | 20191213 |
WO-2021119482-A1 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | 20191213 |
WO-2021115286-A1 | Six-membered and five-membered aromatic ring derivative containing nitrogen heteroatoms which can be used as shp2 inhibitor | 20191210 |
US-2021085677-A1 | Shp2 phosphatase inhibitors and methods of making and using the same | 20190924 |
WO-2021061706-A1 | Shp2 phosphatase inhibitors and methods of making and using the same | 20190924 |
EP-3772513-A1 | Shp2 inhibitors | 20190809 |
WO-2021028362-A1 | Shp2 inhibitors | 20190809 |
Complexity: | 114 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 134.084398327 |
Formal Charge: | 0 |
Heavy Atom Count: | 10 |
Hydrogen Bond Acceptor Count: | 2 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 134.084398327 |
Rotatable Bond Count: | 0 |
Topological Polar Surface Area: | 24.9Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 1.3 |
-
Catalog: BB069173
((1-Chloro-2-methylpropan-2-yl)oxy)trimethylsilane
Detail
-
Catalog: BB067784
((1R,2R)-2-(2,3-Dihydrobenzofuran-4-yl)cyclopropyl)methanamine
Detail
-
Catalog: BB055105
((2R,5S,10aS,10bS)-5-Benzyl-8,10b-bis(benzyloxy)-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)carbamic Acid Benzyl Ester
Detail
-
Catalog: BB069924
((2S,4S)-2-(Chloromethyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methyl 4-Methylbenzenesulfonate
Detail
-
Catalog: BB069928
((2S,4R)-2-(Chloromethyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methyl 4-Methylbenzenesulfonate
Detail
-
Catalog: BB056966
(((3aS,5aR,8aR,8bS)-2,2,7,7-Tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl)-L-arginine
Detail
-
Catalog: BB072639
((2R,3S,4R,5R)-5-(4-(Benzyloxy)-2-oxopyridin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl Dihydrogen Phosphate
Detail
-
Catalog: BB069926
((2R,4R)-2-(Chloromethyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methyl 4-Methylbenzenesulfonate
Detail
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS